Skip to main content
Top
Published in: Endocrine 1/2017

01-10-2017 | Original Article

JMV2894, a novel growth hormone secretagogue, accelerates body mass recovery in an experimental model of cachexia

Authors: Elena Bresciani, Laura Rizzi, Laura Molteni, Monica Ravelli, Antonella Liantonio, Khoubaib Ben Haj Salah, Jean-Alain Fehrentz, Jean Martinez, Robert J. Omeljaniuk, Giuseppe Biagini, Vittorio Locatelli, Antonio Torsello

Published in: Endocrine | Issue 1/2017

Login to get access

Abstract

Oncologic patients subjected to chemotherapy frequently present aphagia, malnutrition, and cachexia. The purpose of this study was to investigate whether selected growth hormone secretagogues including hexarelin, JMV2894 and JMV2951 could antagonize body weight loss and wasting induced by cisplatin administration in rats. The three growth hormone secretagogues behaved as full agonists of the growth hormone secretagogues receptor both in terms of ability to stimulate calcium mobilization in Chinese hamster ovary cells and stimulation of growth hormone release in neonatal rats. Adult rats were (i) treated with vehicle throughout (controls), or (ii) treated with cisplatin (days 1–3) and a growth hormone secretagogues or vehicle, (days 1–12). Body weight and food consumption were measured daily. Although all growth hormone secretagogues caused initial transient acute increases in food intake, the total amount of food eaten by controls and growth hormone secretagogues treated groups over the 12 experimental days was not significantly different. All groups pre-treated with cisplatin lost up to 5–10 % body weight in the first 4 days; they subsequently gained weight at a rate comparable with controls. Interestingly, rats which received JMV2894 demonstrated a faster gain in body weight than any other growth hormone secretagogues treated group and at the end of the protocol reached a weight similar to that of controls. JMV2894 did not stimulate perirenal and epididymal fat accumulation but reduced MuRF mRNA levels in skeletal muscles. In conclusion, our findings demonstrate that JMV2894 antagonizes cisplatin induced weight loss in rats and may prove useful in antagonizing cachexia associated with cancer and chemotherapy in humans.
Appendix
Available only for authorised users
Literature
2.
go back to reference R.H. Mak, W. Cheung, Energy homeostasis and cachexia in chronic kidney disease. Pediatr. Nephrol. 21, 1807–1814 (2006)CrossRefPubMed R.H. Mak, W. Cheung, Energy homeostasis and cachexia in chronic kidney disease. Pediatr. Nephrol. 21, 1807–1814 (2006)CrossRefPubMed
3.
go back to reference B.R. Celli, C.G. Cote, S.C. Lareau, P.M. Meek, Predictors of Survival in COPD: more than just the FEV1. Respir. Med. 102(Suppl 1), S27–S35 (2008)CrossRefPubMed B.R. Celli, C.G. Cote, S.C. Lareau, P.M. Meek, Predictors of Survival in COPD: more than just the FEV1. Respir. Med. 102(Suppl 1), S27–S35 (2008)CrossRefPubMed
4.
go back to reference P.J. Hesketh, S. Van Belle, M. Aapro, F.D. Tattersall, R.J. Naylor, R. Hargreaves et al., Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur. J. Cancer 39, 1074–1080 (2003)CrossRefPubMed P.J. Hesketh, S. Van Belle, M. Aapro, F.D. Tattersall, R.J. Naylor, R. Hargreaves et al., Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur. J. Cancer 39, 1074–1080 (2003)CrossRefPubMed
5.
go back to reference J.D. Hainsworth, P.J. Hesketh, Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results. Semin. Oncol. 19, 14–19 (1992) J.D. Hainsworth, P.J. Hesketh, Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results. Semin. Oncol. 19, 14–19 (1992)
6.
go back to reference N.P. Gullett, G. Hebbar, T.R. Ziegler, Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting. Am. J. Clin. Nutr. 91, 1143S–1147S (2010)CrossRefPubMedPubMedCentral N.P. Gullett, G. Hebbar, T.R. Ziegler, Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting. Am. J. Clin. Nutr. 91, 1143S–1147S (2010)CrossRefPubMedPubMedCentral
7.
go back to reference G. Mantovani, C. Madeddu, Cancer cachexia: medical management. Support Care Cancer 18, 1–9 (2010)CrossRefPubMed G. Mantovani, C. Madeddu, Cancer cachexia: medical management. Support Care Cancer 18, 1–9 (2010)CrossRefPubMed
8.
go back to reference A.M. Wren, L.J. Seal, M.A. Cohen, A.E. Brynes, G.S. Frost, K.G. Murphy et al., Ghrelin enhances appetite and increases food intake in humans. J. Clin. Endocrinol. Metab. 86, 5992 (2001)CrossRefPubMed A.M. Wren, L.J. Seal, M.A. Cohen, A.E. Brynes, G.S. Frost, K.G. Murphy et al., Ghrelin enhances appetite and increases food intake in humans. J. Clin. Endocrinol. Metab. 86, 5992 (2001)CrossRefPubMed
9.
go back to reference A.M. Wren, C.J. Small, C.R. Abbott, W.S. Dhillo, L.J. Seal, M.A. Cohen et al., Ghrelin causes hyperphagia and obesity in rats. Diabetes 50, 2540–2547 (2001)CrossRefPubMed A.M. Wren, C.J. Small, C.R. Abbott, W.S. Dhillo, L.J. Seal, M.A. Cohen et al., Ghrelin causes hyperphagia and obesity in rats. Diabetes 50, 2540–2547 (2001)CrossRefPubMed
10.
go back to reference S. Gnanapavan, B. Kola, S.A. Bustin, D.G. Morris, P. McGee, P. Fairclough et al., The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J. Clin. Endocrinol. Metab. 87, 2988 (2002)CrossRefPubMed S. Gnanapavan, B. Kola, S.A. Bustin, D.G. Morris, P. McGee, P. Fairclough et al., The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J. Clin. Endocrinol. Metab. 87, 2988 (2002)CrossRefPubMed
11.
go back to reference Y.L. Liu, N.M. Malik, G.J. Sanger, P.L. Andrews, Ghrelin alleviates cancer chemotherapy-associated dyspepsia in rodents. Cancer Chemother. Pharmacol. 58, 326–333 (2006)CrossRefPubMed Y.L. Liu, N.M. Malik, G.J. Sanger, P.L. Andrews, Ghrelin alleviates cancer chemotherapy-associated dyspepsia in rodents. Cancer Chemother. Pharmacol. 58, 326–333 (2006)CrossRefPubMed
12.
go back to reference J.M. Garcia, J.P. Cata, P.M. Dougherty, R.G. Smith, Ghrelin prevents cisplatin-induced mechanical hyperalgesia and cachexia. Endocrinology 149, 455–460 (2008)CrossRefPubMed J.M. Garcia, J.P. Cata, P.M. Dougherty, R.G. Smith, Ghrelin prevents cisplatin-induced mechanical hyperalgesia and cachexia. Endocrinology 149, 455–460 (2008)CrossRefPubMed
13.
go back to reference J.A. Chen, A. Splenser, B. Guillory, J. Luo, M. Mendiratta, B. Belinova et al., Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved. J. Cachexia Sarcopenia Muscle 6, 132–143 (2015)CrossRefPubMedPubMedCentral J.A. Chen, A. Splenser, B. Guillory, J. Luo, M. Mendiratta, B. Belinova et al., Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved. J. Cachexia Sarcopenia Muscle 6, 132–143 (2015)CrossRefPubMedPubMedCentral
14.
go back to reference A. Torsello, V. Locatelli, M.R. Melis, S. Succu, M.S. Spano, R. Deghenghi et al., Differential orexigenic effects of hexarelin and its analogs in the rat hypothalamus: indication for multiple growth hormone secretagogue receptor subtypes. Neuroendocrinology 72, 327–332 (2000)CrossRefPubMed A. Torsello, V. Locatelli, M.R. Melis, S. Succu, M.S. Spano, R. Deghenghi et al., Differential orexigenic effects of hexarelin and its analogs in the rat hypothalamus: indication for multiple growth hormone secretagogue receptor subtypes. Neuroendocrinology 72, 327–332 (2000)CrossRefPubMed
15.
go back to reference A. Torsello, R. Grilli, M. Luoni, M. Guidi, M.C. Ghigo, W.B. Wehrenberg et al., Mechanism of action of Hexarelin. I. Growth hormone-releasing activity in the rat. Eur. J. Endocrinol. 135, 481–488 (1996)CrossRefPubMed A. Torsello, R. Grilli, M. Luoni, M. Guidi, M.C. Ghigo, W.B. Wehrenberg et al., Mechanism of action of Hexarelin. I. Growth hormone-releasing activity in the rat. Eur. J. Endocrinol. 135, 481–488 (1996)CrossRefPubMed
16.
go back to reference R. Deghenghi, M.M. Cananzi, A. Torsello, C. Battisti, E.E. Muller, V. Locatelli, GH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sci. 54, 1321–1328 (1994)CrossRefPubMed R. Deghenghi, M.M. Cananzi, A. Torsello, C. Battisti, E.E. Muller, V. Locatelli, GH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sci. 54, 1321–1328 (1994)CrossRefPubMed
17.
go back to reference E. Bresciani, N. Pitsikas, L. Tamiazzo, M. Luoni, I. Bulgarelli, D. Cocchi et al., Feeding behavior during long-term hexarelin administration in young and old rats. J. Endocrinol. Invest. 31, 647–652 (2008)CrossRefPubMed E. Bresciani, N. Pitsikas, L. Tamiazzo, M. Luoni, I. Bulgarelli, D. Cocchi et al., Feeding behavior during long-term hexarelin administration in young and old rats. J. Endocrinol. Invest. 31, 647–652 (2008)CrossRefPubMed
18.
go back to reference A. Moulin, L. Demange, G. Berge, D. Gagne, J. Ryan, D. Mousseaux et al., Toward potent ghrelin receptor ligands based on trisubstituted 1,2,4-triazole structure. 2. Synthesis and pharmacological in vitro and in vivo evaluations. J. Med. Chem. 50, 5790–5806 (2007)CrossRefPubMed A. Moulin, L. Demange, G. Berge, D. Gagne, J. Ryan, D. Mousseaux et al., Toward potent ghrelin receptor ligands based on trisubstituted 1,2,4-triazole structure. 2. Synthesis and pharmacological in vitro and in vivo evaluations. J. Med. Chem. 50, 5790–5806 (2007)CrossRefPubMed
19.
go back to reference L. Demange, D. Boeglin, A. Moulin, D. Mousseaux, J. Ryan, G. Berge et al., Synthesis and pharmacological in vitro and in vivo evaluations of novel triazole derivatives as ligands of the ghrelin receptor 1. J. Med. Chem. 50, 1939–1957 (2007)CrossRefPubMed L. Demange, D. Boeglin, A. Moulin, D. Mousseaux, J. Ryan, G. Berge et al., Synthesis and pharmacological in vitro and in vivo evaluations of novel triazole derivatives as ligands of the ghrelin receptor 1. J. Med. Chem. 50, 1939–1957 (2007)CrossRefPubMed
20.
go back to reference V. Cassina, A. Torsello, A. Tempestini, D. Salerno, D. Brogioli, L. Tamiazzo et al., Biophysical characterization of a binding site for TLQP-21, a naturally occurring peptide which induces resistance to obesity. Biochim. Biophys. Acta 1828, 455–460 (2013)CrossRefPubMed V. Cassina, A. Torsello, A. Tempestini, D. Salerno, D. Brogioli, L. Tamiazzo et al., Biophysical characterization of a binding site for TLQP-21, a naturally occurring peptide which induces resistance to obesity. Biochim. Biophys. Acta 1828, 455–460 (2013)CrossRefPubMed
21.
go back to reference S.G. Cella, V. Locatelli, V. De Gennaro, G.P. Bondiolotti, C. Pintor, S. Loche et al., Epinephrine mediates the growth hormone-releasing effect of galanin in infant rats. Endocrinology 122, 855–859 (1988)CrossRefPubMed S.G. Cella, V. Locatelli, V. De Gennaro, G.P. Bondiolotti, C. Pintor, S. Loche et al., Epinephrine mediates the growth hormone-releasing effect of galanin in infant rats. Endocrinology 122, 855–859 (1988)CrossRefPubMed
22.
go back to reference M.G. Cozzi, A. Zanini, V. Locatelli, S.G. Cella, E.E. Muller, Growth hormone-releasing hormone and clonidine stimulate biosynthesis of growth hormone in neonatal pituitaries. Biochem. Biophys. Res. Commun. 138, 1223–1230 (1986)CrossRefPubMed M.G. Cozzi, A. Zanini, V. Locatelli, S.G. Cella, E.E. Muller, Growth hormone-releasing hormone and clonidine stimulate biosynthesis of growth hormone in neonatal pituitaries. Biochem. Biophys. Res. Commun. 138, 1223–1230 (1986)CrossRefPubMed
23.
go back to reference S.G. Cella, V. Locatelli, V. de Gennaro, R. Puggioni, C. Pintor, E.E. Muller, Human pancreatic growth hormone (GH)-releasing hormone stimulates GH synthesis and release in infant rats. An in vivo study. Endocrinology 116, 574–577 (1985)CrossRefPubMed S.G. Cella, V. Locatelli, V. de Gennaro, R. Puggioni, C. Pintor, E.E. Muller, Human pancreatic growth hormone (GH)-releasing hormone stimulates GH synthesis and release in infant rats. An in vivo study. Endocrinology 116, 574–577 (1985)CrossRefPubMed
24.
go back to reference D.T. Dickey, L.L. Muldoon, N.D. Doolittle, D.R. Peterson, D.F. Kraemer, E.A. Neuwelt, Effect of N-acetylcysteine route of administration on chemoprotection against cisplatin-induced toxicity in rat models. Cancer Chemother. Pharmacol. 62, 235–241 (2008)CrossRefPubMed D.T. Dickey, L.L. Muldoon, N.D. Doolittle, D.R. Peterson, D.F. Kraemer, E.A. Neuwelt, Effect of N-acetylcysteine route of administration on chemoprotection against cisplatin-induced toxicity in rat models. Cancer Chemother. Pharmacol. 62, 235–241 (2008)CrossRefPubMed
25.
go back to reference A. Inui, Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J. Clin. 52, 72–91 (2002)CrossRefPubMed A. Inui, Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J. Clin. 52, 72–91 (2002)CrossRefPubMed
26.
go back to reference J.S.S.M. Damrauer, S. Acharyya, A.S. Baldwin, M.E. Couch, D.C. Guttridge, Chemotherapy-induced muscle wasting: association with NF-kB and cancer cachexia. Basic Appl. Myol. 18, 139–148 (2008) J.S.S.M. Damrauer, S. Acharyya, A.S. Baldwin, M.E. Couch, D.C. Guttridge, Chemotherapy-induced muscle wasting: association with NF-kB and cancer cachexia. Basic Appl. Myol. 18, 139–148 (2008)
27.
go back to reference M.D. DeBoer, X.X. Zhu, P. Levasseur, M.M. Meguid, S. Suzuki, A. Inui et al., Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology 148, 3004–3012 (2007)CrossRefPubMed M.D. DeBoer, X.X. Zhu, P. Levasseur, M.M. Meguid, S. Suzuki, A. Inui et al., Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology 148, 3004–3012 (2007)CrossRefPubMed
28.
go back to reference M.D. Deboer, X. Zhu, P.R. Levasseur, A. Inui, Z. Hu, G. Han et al., Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. Endocrinology 149, 827–835 (2008)CrossRefPubMed M.D. Deboer, X. Zhu, P.R. Levasseur, A. Inui, Z. Hu, G. Han et al., Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. Endocrinology 149, 827–835 (2008)CrossRefPubMed
29.
go back to reference S. Perboni, C. Bowers, S. Kojima, A. Asakawa, A. Inui, Growth hormone releasing peptide 2 reverses anorexia associated with chemotherapy with 5-fluoruracil in colon cancer cell-bearing mice. World J. Gastroenterol. 14, 6303–6305 (2008)CrossRefPubMedPubMedCentral S. Perboni, C. Bowers, S. Kojima, A. Asakawa, A. Inui, Growth hormone releasing peptide 2 reverses anorexia associated with chemotherapy with 5-fluoruracil in colon cancer cell-bearing mice. World J. Gastroenterol. 14, 6303–6305 (2008)CrossRefPubMedPubMedCentral
30.
go back to reference D. Yamamoto, N. Ikeshita, T. Matsubara, H. Tasaki, E.H. Herningtyas, K. Toda et al., GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1. Life Sci. 82, 460–466 (2008)CrossRefPubMed D. Yamamoto, N. Ikeshita, T. Matsubara, H. Tasaki, E.H. Herningtyas, K. Toda et al., GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1. Life Sci. 82, 460–466 (2008)CrossRefPubMed
31.
go back to reference M.D. DeBoer, Update on melanocortin interventions for cachexia: progress toward clinical application. Nutrition 26, 146–151 (2010)CrossRefPubMed M.D. DeBoer, Update on melanocortin interventions for cachexia: progress toward clinical application. Nutrition 26, 146–151 (2010)CrossRefPubMed
32.
go back to reference G. Muccioli, N. Pons, C. Ghe, F. Catapano, R. Granata, E. Ghigo, Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor. Eur. J. Pharmacol. 498, 27–35 (2004)CrossRefPubMed G. Muccioli, N. Pons, C. Ghe, F. Catapano, R. Granata, E. Ghigo, Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor. Eur. J. Pharmacol. 498, 27–35 (2004)CrossRefPubMed
33.
go back to reference N.M. Thompson, D.A. Gill, R. Davies, N. Loveridge, P.A. Houston, I.C. Robinson et al., Ghrelin and des-octanoyl ghrelin promote adipogenesis directly in vivo by a mechanism independent of the type 1a growth hormone secretagogue receptor. Endocrinology 145, 234–242 (2004)CrossRefPubMed N.M. Thompson, D.A. Gill, R. Davies, N. Loveridge, P.A. Houston, I.C. Robinson et al., Ghrelin and des-octanoyl ghrelin promote adipogenesis directly in vivo by a mechanism independent of the type 1a growth hormone secretagogue receptor. Endocrinology 145, 234–242 (2004)CrossRefPubMed
34.
go back to reference M. Sugiyama, A. Yamaki, M. Furuya, N. Inomata, Y. Minamitake, K. Ohsuye et al., Ghrelin improves body weight loss and skeletal muscle catabolism associated with angiotensin II-induced cachexia in mice. Regul. Pept. 178, 21–28 (2012)CrossRefPubMed M. Sugiyama, A. Yamaki, M. Furuya, N. Inomata, Y. Minamitake, K. Ohsuye et al., Ghrelin improves body weight loss and skeletal muscle catabolism associated with angiotensin II-induced cachexia in mice. Regul. Pept. 178, 21–28 (2012)CrossRefPubMed
35.
go back to reference E.A. Nijland, C.J. Strasburger, C. Popp-Snijders, P.S. van der Wal, E.A. van der Veen, A five day treatment with daily subcutaneous injections of growth hormone-releasing peptide-2 causes response attenuation and does not stimulate insulin-like growth factor-I secretion in healthy young men. Eur. J. Endocrinol. 139, 395–401 (1998)CrossRefPubMed E.A. Nijland, C.J. Strasburger, C. Popp-Snijders, P.S. van der Wal, E.A. van der Veen, A five day treatment with daily subcutaneous injections of growth hormone-releasing peptide-2 causes response attenuation and does not stimulate insulin-like growth factor-I secretion in healthy young men. Eur. J. Endocrinol. 139, 395–401 (1998)CrossRefPubMed
36.
go back to reference M. Tschop, M.A. Statnick, T.M. Suter, M.L. Heiman, GH-releasing peptide-2 increases fat mass in mice lacking NPY: indication for a crucial mediating role of hypothalamic agouti-related protein. Endocrinology 143, 558–568 (2002)CrossRefPubMed M. Tschop, M.A. Statnick, T.M. Suter, M.L. Heiman, GH-releasing peptide-2 increases fat mass in mice lacking NPY: indication for a crucial mediating role of hypothalamic agouti-related protein. Endocrinology 143, 558–568 (2002)CrossRefPubMed
37.
go back to reference K. Burckart, S. Beca, R.J. Urban, M. Sheffield-Moore, Pathogenesis of muscle wasting in cancer cachexia: targeted anabolic and anticatabolic therapies. Curr. Opin. Clin. Nutr. Metab. Care 13, 410–416 (2010)CrossRefPubMedPubMedCentral K. Burckart, S. Beca, R.J. Urban, M. Sheffield-Moore, Pathogenesis of muscle wasting in cancer cachexia: targeted anabolic and anticatabolic therapies. Curr. Opin. Clin. Nutr. Metab. Care 13, 410–416 (2010)CrossRefPubMedPubMedCentral
38.
go back to reference J.S. Temel, A.P. Abernethy, D.C. Currow, J. Friend, E.M. Duus, Y. Yan et al., Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 17, 519–531 (2016)CrossRefPubMed J.S. Temel, A.P. Abernethy, D.C. Currow, J. Friend, E.M. Duus, Y. Yan et al., Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 17, 519–531 (2016)CrossRefPubMed
Metadata
Title
JMV2894, a novel growth hormone secretagogue, accelerates body mass recovery in an experimental model of cachexia
Authors
Elena Bresciani
Laura Rizzi
Laura Molteni
Monica Ravelli
Antonella Liantonio
Khoubaib Ben Haj Salah
Jean-Alain Fehrentz
Jean Martinez
Robert J. Omeljaniuk
Giuseppe Biagini
Vittorio Locatelli
Antonio Torsello
Publication date
01-10-2017
Publisher
Springer US
Published in
Endocrine / Issue 1/2017
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-1184-2

Other articles of this Issue 1/2017

Endocrine 1/2017 Go to the issue